Dr. Reddy's faces Semaglutide supply halt due to impurity; resumes by Oct/Nov
Dr. Reddy's halts Semaglutide injection supply due to an impurity found during scale-up. Resumption expected by late Oct/early Nov 2026, targeting 6-7 million pens for Q3/Q4 FY27. Investigation and validation to conclude by September. No patient safety impact or recall necessary.
The supply interruption of a key product like Semaglutide, even if temporary, will likely affect revenue for the affected quarters and requires significant management attention to resolve. While not a complete product failure, it introduces uncertainty and potential financial impact.
The announcement details a supply halt and potential delays due to a quality issue, which negatively impacts current and near-term commercial operations.
Dr. Reddy's Laboratories Limited has announced a temporary halt in the commercial supply of its Semaglutide injection due to an impurity found in a scaled-up API manufacturing batch. While the API met specifications, a finished drug product test revealed an impurity, indicating degradation during formulation. The company is investigating the root cause and implementing process improvements.
The company expects to resume commercial supplies by late October or early November, aiming to supply 6-7 million pens between Q3 and Q4 of FY27, subject to successful validation of the revised manufacturing process. This validation process, including making adjustments, testing three validation batches, and sending them for drug product testing, is anticipated to take until September.
Dr. Reddy's has assured that its manufacturing facilities remain compliant with global regulatory requirements, and there is no impact on existing global regulatory filings or patient safety for products already supplied to the market. The supply of Semaglutide oral tablets is also unaffected as it uses a different API source. The company is exploring alternative suppliers but anticipates this would take about a year due to pre-approval supplement requirements, making it unsuitable for near-term needs. There are no plans to recall any product already in the market.
What to do with a filing like this
Dr. Reddy's Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under other company updates. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Dr. Reddy's Laboratories Limited. Read the original for the full detail.